Heart Failure With Preserved Ejection Fraction: Current Status and Future Opportunities

An in-depth discussion on the clinical and economic burden of treatment for patients with heart failure, with special consideration to progressive disease.

An expert in the management of heart failure provides an overview of the progressive nature of the disease, with special consideration to biomarker monitorization.

A discussion on the link between LVEF, nT-proBNP, and cardiac remodeling in predicting disease progression.

A key opinion leader discusses how the medical understanding of heart failure has improved over the years and how it has helped management of disease.

Expert physicians consider the treatment goals for patients with heart failure.

An expert in the management of heart failure discusses the standard of care for patients with reduced ejection fraction.

Key opinion leaders provide an overview of the treatment gaps in the management of heart failure.

A discussion on utilization management strategies for optimizing the treatment for patients with heart failure.

Key opinion leaders enumerate the challenges of treating patients with HFpEF.

Expert physicians consider how the treatment of patients differ when they have HFpEF versus HFrEF.

A key opinion leader considers how to ensure patients with HFpEF and HFrEF receive therapy in a timely and appropriate manner.

A discussion on how the economic burden of management differs for patients with HFpEF and HFrEF.

An expert physician provides an overview of the PROVE-HF trial and considers the practical implications for heart failure with reduced ejection fraction.

An overview of the PARAGON-HF trial with special consideration to the rationale behind the design, the cardiovascular end points, and the safety profile.

An expert in the management of heart failure considers the importance of recent findings from the PARALLAX study.

A discussion on the promising findings from the TOPCAT study.

A discussion on the differences of sacubitril-valsartan and spironolactone for the treatment of heart failure.

A key opinion leader considers the optimal timing of adding an SGLT2 inhibitor to the treatment for patients with heart failure.

A discussion on the optimal sites of care for patients with heart failure and how differing locations may alter treatment access.

Expert physicians consider how novel agents will affect the treatment paradigm for heart failure.

The program is closed with a discussion on how the coronavirus pandemic has affected the standard protocol for treating patients with heart failure.